Results 231 to 240 of about 211,965 (305)
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
Potential Medicare Part D Savings on Ophthalmic Generic Drugs.
Collet DA, Urban MB, Amin A.
europepmc +1 more source
ABSTRACT Family members may be impacted by complex care requirements around childhood disability, although little research provides guidance on the changing needs of families under unexpected circumstances. This study investigated parents' experiences and reports of the impact of COVID‐19 lockdowns in Australia on family members in families raising a ...
Helen Bourke‐Taylor +6 more
wiley +1 more source
Health insurance and labor supply: Evidence from same‐sex couples
Abstract This paper examines labor supply effects of policies allowing public sector workers to include same‐sex partners in employer‐sponsored insurance plans. Unlike broader partnership recognition rights, these policies focus narrowly on insurance access.
Elisabeth Wurm
wiley +1 more source
Analyzing the relationship between socioeconomic deprivation and outpatient Medicare Part D fluoroquinolone claim rates in Texas. [PDF]
Al Mohajer M +3 more
europepmc +1 more source
Frailty, Specialized Care, and Sociodemographic Factors: Disparities in Oral Pharmacotherapy Class Utilization Among Medicare Part D Beneficiaries With Overactive Bladder in the United States. [PDF]
Enemchukwu EA +5 more
europepmc +1 more source
Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB.
europepmc +1 more source

